34312 Treatment with amlitelimab (KY1005, SAR445229): A novel nondepleting anti-OX40Ligand (OX40L) mAb reduces IL-13 serum levels in a phase 2a randomized placebo-controlled trial in patients with moderate to severe atopic dermatitis

Saved in:
Bibliographic Details
Published inJournal of the American Academy of Dermatology Vol. 87; no. 3; p. AB123
Main Authors Weidinger, Stephan, Bieber, Thomas, Cork, Michael
Format Journal Article
LanguageEnglish
Published Elsevier Inc 01.09.2022
Online AccessGet full text

Cover

More Information
ISSN:0190-9622
1097-6787
DOI:10.1016/j.jaad.2022.06.525